P
PRISM BioLab
PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform
About PRISM BioLab
PRISM BioLab is a biotechnology company that leverages its proprietary PepMetics Technology to revolutionize drug discovery. Founded in 2006 by a team of dedicated scientists, the company focuses on creating new drugs based on peptide mimetic small molecules. Over more than a decade of research and development, PRISM BioLab has built a robust clinical pipeline and discovered numerous potential seed compounds.
Read full description
The company operates in the pharmaceutical and biotechnology markets, serving clients ranging from academic researchers to large pharmaceutical companies. PRISM BioLab's business model revolves around licensing its proprietary technology and compounds, as well as forming strategic partnerships for drug development. Revenue is generated through licensing fees, milestone payments, and royalties from successfully developed drugs.
PRISM BioLab is committed to scientific innovation and open collaboration, inviting all levels of scientific discussion to maximize the potential of its technology.
At a glance
- Founded
- 2006
- Headquarters
- Fujisawa, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
DBJ Capital
Series B and later6 investors entered at this stage
Daiwa Corporate Investment
Eisai
Newton BioCapital
INCJ
SANTEC
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PRISM BioLab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PRISM BioLab on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.